| Document Date: 2014-09-22 14:00:28
Open Document File Size: 87,60 KBShare Result on Facebook
City Leiden / Chicago / / Company Medical Research Network / Greenphire / Prosensa Holding N.V. / / Continent North America / Europe / / Country Netherlands / Japan / United States / Canada / United Kingdom / / Event Business Partnership / FDA Phase / / Facility Leiden University Medical Center / / IndustryTerm qualified nursing networks / technology patients / feasibility tool / technology innovations / biotechnology / home healthcare / web-based technology / home healthcare services / therapeutics for rare diseases / travel arrangements / social media / expert travel services / clinical payment technology / biopharmaceutical company focusing / therapeutics for the treatment of genetic disorders / travel time / exon skipping technology / / MedicalCondition muscular dystrophy / rare diseases / orphan diseases / rare neuromuscular and neurodegenerative disorders / disease / severely debilitating childhood neuromuscular disease / Myotonic dystrophy / rare disease / respiratory and cardiac failure / Huntington's disease / genetic disorders / / Organization Leiden University Medical Center / United States Food and Drug Administration / IMP administration / European Union / / Person Giles Campion / Hans Schikan / / Position Chief Executive Officer / Chief Medical Officer / / Product ClinCard System / United States / / Technology biotechnology / exon skipping technology / clinical payment technology / web-based technology / genetic code / / URL www.prosensa.com / www.Greenphire.com / /
SocialTag |
Prosensa announces commencement of redosing of drisapersen in North America in patients with Duchenne muscular dystrophy Leiden, The Netherlands, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), th